Rhythm Pharma shareholders elect three directors, approve equity plan at annual meeting

RHYTHM PHARMACEUTICALS, INC.

Elected Class I directors: Stuart Arbuckle (45.6M for), Christophe Jean (45.0M), Lynn Tetrault (45.5M).
Ratified Ernst & Young as auditor: 53.8M for, 69.5K against.
Advisory vote on executive compensation: 50.6M for, 1.5M against.
Reapproved 2017 Equity Incentive Plan: 32.7M for, 19.4M against (63% of votes cast).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.